Placeholder

Striking a Balance for Innovation

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1230. Categories: , .

Product Description

For hundreds of years, patents protecting intellectual property have been recognized as incentives for innovation. The U.S. constitution contains a line that underscores this understanding, that “Congress shall have the power to … promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries.”
In the pharmaceutical industry, patent protection of intellectual property and assets is a particularly important way for brand-name drug manufacturers to recoup the tremendous investment made in research and development — not just for those drugs that make it to market but for those drug candidates that failed during development.
For years the pharmaceutical industry’s practices for protecting its intellectual property have been scrutinized by public citizen groups and challenged by generic manufacturers.

Sidebars:
Anticompetituve or Sound Business Strategy?
Leading Blockbusters Going Off Patent

Experts on this Topic
Peter Gerken. VP and practice leader of the intellectual property practice, Marsh Inc., New York; Marsh is a leading risk and insurance services firm. For more information, visit marsh.com.
Charles Guttman. Partner, intellectual property department, Proskauer Rose LLP, New York; Proskauer Rose is a law firm with experience in all areas of practice, including corporate finance, mergers and acquisitions, real estate transactions, bankruptcy and reorganizations, taxation, litigation, intellectual property, and labor and employment law. For more information, visit proskauer.com.
Albert L. Jacobs Jr. Chair, national intellectual property department, and cochair of the national biotechnology group, Greenberg Traurig LLP, New York; Greenberg Traurig is a law firm serving information technology, energy,
entertainment, telecommunications, and healthcare clients. For more information, visit gtlaw.com.
Dr. Mervyn Jacobson. Executive chairman and cofounder, Genetic Technologies Ltd., Melbourne, Australia; Genetic
Technologies has invented strategies to use the information within the noncoding sequences of DNA for use in diagnostics and for mapping and identification of markers of interest. For more information, visit gtg.com.au.
Kathi Kedrowski. Partner, the Global Investigations & Dispute Advisory practice, and leader, the intellectual asset solutions practice, Ernst & Young, Chicago; Ernst & Young is a global leader in professional services that helps companies to identify and capitalize on business opportunities. For more information, visit ey.com.
John Lucas, Ph.D., J.D. VP, chief patent counsel, TransForm Pharmaceuticals Inc., Lexington, Mass.; TransForm is optimizing drug forms and/or formulations and increasing the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. For more information, visit transformpharma.com.
Barak Pridor. CEO, ClearForest Corp., New York; ClearForest provides next generation unstructured data management (UDM)
software products. For more information, visit clearforest.com.
Richard Reed. VP, Chubb & Son, and global intellectual property and e-commerce practice leader, Chubb Commercial Insurance, Warren, N.J.; The Chubb Corp. provides property and casualty insurance for personal and commercial customers worldwide through 8,000 independent agents and brokers. For more information, visit chubb.com.
Scott Requadt. Director, business development, TransForm Pharmaceuticals Inc., Lexington, Mass.; TransForm is optimizing drug forms and/or formulations and increasing the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. For more information, visit transformpharma.com.
Patrick H. Sullivan. Senior president, Intellectual Capital Management Group Inc. (ICMG), Palo Alto, Calif.; ICMG, an
Acorn Technologies company, is a management consulting and asset management firm specializing in how to systematically extract value from intangibles such as knowledge, know-how, innovation, intellectual assets, and intellectual property. For more information, visit icmgroup.com.
Jeff Trewhitt. Spokesman, Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, D.C.; PhRMA represents the country’s leading research-based pharmaceutical and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. For more information, visit phrma.org.

FEEDBACK